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Specific Nutrients and Their Relevance to Disease
Constituents of a Diet that 
Support Healthy Systemic 
and Ocular function
vitamin C 
L inus Pauling brought Vita-min C to the forefront of  healthcare by advocating 
mega-doses of  Vitamin C to fight 
colds and minimize the risk of  can-
cer. Even recently studies continue 
to corroborate his presumptions. 
The new information relates that 
the group most prone to enjoy the 
benefits of  Vitamin C for the com-
mon cold are those individuals under 
heavy short-term physical stress. 280 
Vitamin C is a water-soluble antioxi-
dant working in concert with Vita-
min E. Vitamin C must be obtained 
from the diet with absence creating 
the disease, scurvy. Early symptoms 
of  scurvy include fatigue resulting 
from lowered levels of  carnitine and 
norepinephrine.281
Vitamin C (Ascorbic Acid) is re-
quired for collagen synthesis, the 
synthesis of  norepinephrine, carni-
tine and the conversion of  choles-
terol to bile acids.  The overwhelm-
ing fame of  Vitamin C is associated 
with its role as an antioxidant for 
the protection of  molecules from 
damage by free radicals and reac-
tive oxygen species (ROS) created 
during metabolism and toxin expo-
sure such as smoking which creates 
oxidative stress.
IOP can be reduced by increasing 
concentrations of  absorbate in the 
aqueous humor.  This can be done 
by supplementing with vitamin C 
(0.5 gm/kg body weight). The IOP-
lowering actions of  vitamin C oc-
cur by improving collagen forma-
tion, increasing blood osmolarity, 
improving aqueous outflow, inhib-
iting lipid peroxidation and raising 
glutathione levels.282-284 Vitamin C 
is known as a very active antioxi-
dant that also creates an increase in 
Immunoglobulin A (IgA) and Im-
munoglobulin M (IgM) within the 
framework of  the immune system. 
There is the suggestion that vi-
tamin supplementation suppresses 
leukocyte adhesion and thus endo-
thelial dysfunction, associated with 
increase in iris blood flow perfu-
sion in diabetes. It has also been 
suggested that the antioxidant vita-
min C may be a therapeutic agent 
for preventing diabetic retinopathy. 285 
Diabetes mellitus is associated with 
increased oxidative stress. One 
study suggests that supplementa-
tion with antioxidant vitamins C 
and E probably plays an important 
role in improving the constitution 
of  the ocular surface in the patient 
with diabetes.286 Plasma vitamin C 
levels are inversely associated with 
the risk for type 2 diabetes.  There 
is an inverse association between 
fruit and vegetable intake and the 
risk for type 2 diabetes, with a 
greater effect for fruit intake.287 Re-
garding Vitamin C as a part of  an 
anti-Age Related Macular Degen-
eration formula, it has been shown 
that blue light could induce DNA 
damage to RPE cells but vitamin C 
could protect the RPE cells from 
the blue light-induced DNA dam-
age.288 Regarding anterior segment, 
the addition of  ascorbic acid to 
the irrigation solution reduced the 
amount of  endothelial cell loss 
during phacoemulsification by ap-
proximately 70%.289 Likewise a sig-
nificantly reduced mean level of  
ascorbic acid was observed in the 
aqueous humor of  patients with 
exfoliation syndrome in one study. 
In view of  the fact that ascorbic 
acid is a major protective factor 
against free radical action, a role 
for free radical action is suggested 
as a possible factor in the genesis 
of  exfoliation syndrome.290  
The utilization of  Vitamin C for 
the prevention of  cataract has long 
been in the literature.  While stud-
ies continue to be controversial one 
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study showed the risk for cataract 
is 60% lower among persons who 
use multivitamins or any supple-
ment containing vitamin C or E 
for more than 10 years. However 
the use of  vitamins for shorter 
duration is not associated with re-
duced risk for cataract.291 Another 
study demonstrated that Vitamin 
C reduced the risk of  cortical cat-
aracts in women aged 60 years or 
less and carotenoids reduce the risk 
of  posterior subcapsular cataract in 
women who have never smoked.292  
Research by the Nutrition and Vi-
sion Project (NVP), a cooperative 
effort of  Harvard and Tufts Uni-
versity scientists, has found that 
women who consume higher-than-
recommended doses of  vitamin C 
may lower their risk for more than 
one type of  cataract.293 
Immune system activities of  Vi-
tamin C are extensive. Vitamin C 
enhances prostaglandin E1 (PGE1) 
and thus assists in the regulation of  
T cell function. Vitamin C increas-
es killer T cell activity and B cell 
function.  It also increases glutathi-
one levels. It is known to protect 
against viruses by strengthening 
connective tissue and neutralizing 
toxins released by phagocytes. The 
RDA for Vitamin C is 100 to 125 
mg/day. The tolerable upper level 
for vitamin C is established at 2000 
mg/day. 294  Daily supplementation 
of  vitamin C is recommended with 
consideration for the increased 
risk for kidney stones. 295 Recom-
mended levels vary considerably 
with the sources and care should 
be exercised when evaluating these 
variables.    
Potential harms of  all variations 
of  high-dose antioxidant supple-
mentation must be considered. 
These may include an increased risk 
of  lung cancer in smokers (beta-
carotene), kidney stones, heart fail-
ure in people with vascular disease 
or diabetes (vitamin E) and hospi-
talization for genitourinary condi-
tions (zinc). 
vitamin D
Vitamin D is a fat-soluble vitamin 
(in actual fact a steroid hormone) 
essential for promoting calcium ab-
sorption in the gut and maintaining 
adequate serum calcium and phos-
phate concentrations to enable 
normal mineralization of  bone and 
to prevent hypocalcemic tetany. It 
is also needed for bone growth and 
bone remodeling.296 Severe Vitamin 
D deficiency in infants and children 
results in rickets with growth plate 
enlarging without the support of  
mineralization of  the long bones. 
This results in bowing.  Vitamin 
D3 (cholecalciferol) can be synthe-
sized by humans in the skin upon 
exposure to ultraviolet-B (UVB) 
radiation. It can also be obtained 
from the diet, but is fat-soluble. 
Sufficient vitamin D prevents rick-
ets in children and osteomalacia in 
adults and, together with calcium, 
vitamin D helps protect older 
adults from osteoporosis. A quan-
titative meta-analysis recently con-
cluded that at a mean daily dose of  
vitamin D of  528 IU there was a 
significant decrease in death (7% 
to 8%) for those using vitamin D 
supplement. 297
It has been estimated that 50% to 
60% of  people do not have satis-
factory vitamin-D status, likely re-
lated to urbanization, demographic 
shifts, decreased outdoor activity, 
air pollution and global dimming, 
as well as decreases in the cutane-
ous production of  vitamin D with 
age. One prospective cohort study 
demonstrates for the first time 
that low 25-hydroxyvitamin-D and 
1,25-dihydroxyvitamin-D levels are 
associated with increased risk in all-
cause and cardiovascular mortality 
compared with patients with higher 
serum vitamin-D levels.298-300 An-
other recent study found that 40.7% 
of  patients with chronic migraine 
were deficient in 25-hydroxyvita-
min D. The study also showed that 
the longer individuals had chronic 
migraine, the more likely they were 
to be vitamin D deficient. 301
Vitamin D deficiency is wide-
spread among patients being 
treated for osteoporosis, and such 
deficiency should be treated ag-
gressively.302 Recent reports have 
increased the awareness of  a much 
broader role for vitamin D. Vitamin 
D is involved in differentiation of  
tissues during development and in 
proper functioning of  the immune 
system. Over 900 different genes 
are now known to be able to bind 
the vitamin D receptor, through 
which vitamin D mediates its ef-
fects. The majority of  effects of  
vitamin D in the body are related to 
the activity of  1,25(OH)2D includ-
ing 50 specific genes. 1,25(OH)2D 
also inhibits proliferation and stim-
ulates differentiation of  cells as well 
as having activity as an immune 
C a n a d i a n  J o u r n a l  o f  o p t o m e t r y
r e v u e  C a n a d i e n n e  d ’ o p t o m é t r i e
Vol 71  No 5
October / octobre 200910
system modulator. It is even sug-
gested that 1,25(OH)2D may en-
hance innate immunity and protect 
against many autoimmune disor-
ders.303-304 Evidence also continues 
to accumulate suggesting a benefi-
cial role for vitamin D in protect-
ing against autoimmune diseases, 
including multiple sclerosis and type 
I diabetes, as well as some forms 
of  cancer, particularly colorectal 
and breast.305-306  Most biological ef-
fects of  Vitamin D are mediated 
through a nuclear transcription fac-
tor VDR.307-309 A recent article con-
cludes that there is ample biological 
evidence to suggest an important 
role for vitamin D in brain develop-
ment and function, and that supple-
mentation for groups chronically 
low in vitamin D is warranted. Since 
Calcium is so linked to neurodegenera-
tion, one may hypothesize a link between 
Vitamin D, the immune system and the 
negative actions of the calcium ion.310
Hypovitaminosis D, especially at 
levels less than 30 ng/mL, is associ-
ated with an increased risk for Myo-
cardial Infarct in men. Vitamin D is 
likely to exert its effect on the risk 
for cardiovascular disease via vascu-
lar smooth muscle cell proliferation, 
inflammation, vascular calcifica-
tion, the renin-angiotensin system, 
and blood pressure.311-312 The rate 
of  cardiovascular disease–related 
deaths is greater at higher latitudes, 
lower at higher altitudes, and higher 
in the winter months — all asso-
ciations related to vitamin D defi-
ciency. The vitamin D axis affects 
vascular smooth muscle cell pro-
liferation, inflammation, vascular 
calcification, the renin-angiotensin 
system, and blood pressure, all of  
which affect cardiovascular disease 
and MI risk, but evidence linking 
hypovitaminosis D and MI is sparse. 
Current recommendations for vita-
min D are 200 to 600 IU per day, 
which may be inadequate to prevent 
cardiovascular disease. Another re-
cent study demonstrated that use 
of  calcitriol in patients with stage 
III or IV Chronic Kidney Disease 
(CKD) with hyperparathyroidism 
is associated with reduced risk for 
mortality and long-term dialysis and 
that the use of  calcitriol in patients 
with stage III or IV CKD with hy-
perparathyroidism is associated with 
increased risk for hypercalcemia. 
CKD affects more than 10% of  the 
US population with disturbances in 
vitamin D and mineral metabolism. 313
For the first time Vitamin D defi-
ciency has been linked to a poorer 
outcome in breast cancer.314 Risk 
factors for Vitamin D deficiency in-
clude: dark skin, sunscreens, cloth-
ing covering the majority of  the 
skin, increasing age, gastrointestinal 
disorders associated with fat malab-
sorption, obesity, bariatric surgery, 
ill-advised dieting,  and a poor diet. 
The results of  most clinical trials 
suggest that vitamin D supplemen-
tation can slow bone density losses 
or decrease the risk of  osteoporotic 
fracture in men and women.315-318 
but the issue is still very controver-
sial.  Indeed, vitamin D3 (cholecal-
ciferol) is now known to be greater 
than three times more potent than 
vitamin D2.319-320 In order for vita-
min D supplementation to be ef-
fective in preserving bone health, 
adequate dietary calcium (1,000 to 
1,200 mg/day) should also be con-
sumed. In general adults should take 
a supplement that supplies 400IU of  
vitamin D3 daily and should have 10-
15 minutes of  sun exposure at least 
three times a week as close to noon as 
possible. Should sunlight exposure be 
unattainable, 800IU of  D3 is advised. 
In reality it is best to aim for serum 
levels of  80 nmol/L to minimize risk 
of  disease. Toxicity-hypercalcemia 
can lead to bone loss, kidney stones, 
and calcification of  the heart and 
kidneys. Because the consequences 
of  hypervitaminosis D and ensuing 
hypercalcemia are severe, the Food 
and Nutrition Board established a 
very conservative upper limit of  
2,000 IU/day (50 mcg/day) for 
children and adults 321 while other 
reports suggest 10,000IU is toler-
ated.322-323
A recent study, while equating low 
vitamin D levels to an increased risk 
of  mortality, concludes that they 
would not advise people to take 
supplements without knowing their 
vitamin-D levels and that the most 
sensible advice for those wanting to 
ensure their levels remain optimal 
is to spend 10 to 15 minutes per 
day in the sun and to eat vitamin-
D-fortified foods, such as milk and 
oily fish.324
More recent studies relate the im-
portance of  Vitamin D3 to the eyes. 
Based on encouraging preliminary 
findings, more study is recommend-
ed on the benefit of  antioxidant 
supplements for age-related macu-
lar degeneration and of  selenium 
for cancer prevention. In contrast to 
the state of  the art for antioxidant 
supplements, there is strong and 
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compelling support for the health 
benefits of  supplements of  Vitamin 
D and calcium when intake/status 
of  these nutrients is not optimal. 
Thus, specific recommendations for 
these supplements in older adults 
are warranted. 325  It has been shown 
that Levels of  serum vitamin D 
were inversely associated with early 
AMD but not advanced AMD and 
that milk intake was inversely associ-
ated with early AMD.  Coincidently 
fish intake was inversely associated 
with advanced AMD in this report. 
It was reported that consistent use 
vs nonuse of  vitamin D from sup-
plements was inversely associated 
with early AMD only in individuals 
who did not consume milk daily.326 
Carrying this one step further, it 
was found that Higher levels of  
Bone Mineral Density (BMD) may 
be associated with lower risk for 
ARM. The underlying mechanism is 
unknown, although BMD may be a 
marker for lifetime endogenous es-
trogen exposure.327
Vitamin D is present in only a 
few foods (e.g. fatty fish), and is 
also added to fortified milk, but our 
supply typically comes mostly from 
exposure to ultraviolet rays (UV) in 
sunlight. UV from the sun converts 
a biochemical in the skin to vita-
min D, which is then metabolized 
to calcitriol, its active form and an 
important hormone. Formation of  
vitamin D by UV can be 6 times 
more efficient in light skin than dark 
skin, which is an important cause of  
the known widespread vitamin D 
deficiency among African Ameri-
cans living in northern latitudes. 
The issue of  how Vitamin D relates 
to the general and ocular health of  
individuals is evolving with research 
outstripping one’s ability to “keep 
up.” A recent AARP magazine 
presented the following as cited by 
Michael F. Holick PhD, MD of  the 
Vitamin D, Skin and Bone Research 
Laboratory of  Boston University 
Medical Center.
“To get the vitamin D value of  ten 
minutes’ exposure to sunlight, you’d 
have to eat… 6 ½ pounds of  shitake 
mushrooms or 150 egg yolks or 3 ¾ 
pounds of  fresh farmed salmon or 
30 servings of  fortified cereal or 2 
1/6 pounds of  sardines or 30 cups 
of  fortified orange juice.” Do the 
calorie count on that exercise and 
realize that food sources of  vitamin 
D actually complicate the issue.
vitamin E
Alpha-tocopherol is the only form 
of  Vitamin E in the human body 
and is the form recommended for 
supplementation. Vitamin E is the 
body’s primary fat-soluble antioxi-
dant and it must be obtained from 
food or supplements. As an antioxi-
dant Alpha-tocopherol neutralizes 
free radicals then must be trans-
formed back to Alpha-tocopherol 
with the assistance of  other antioxi-
dants such as Vitamin C.  Vitamin E 
travels through the body in low-den-
sity liporoteins which protect them 
from from oxidation. Vitamin E is 
known to affect the expression and 
activity of  immune and inflamma-
tory cells, to enhance vasodilation 
and to inhibit the activity of  the cell 
signaling molecule protein kinase 
C (PKC). Modulating the PKC 
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pathway may be relevant in glaucoma 
as PKC inhibitors relax the trabecu-
lar meshwork and affect matrix me-
talloproteinase and PGF2 alpha.328 It 
has been shown that retinal vascular 
dysfunction due to hyperglycemia 
was prevented by vitamin E.329 It has 
also been reported that vitamin E as 
d-alpha tocopheryl acetate in 300 to 
600 mg/day dosages improved blood 
flow and reduced visual field change 
in glaucomatous eyes.330
Alpha-tocopherol at 400 to 800 
IU per day is an effective antioxi-
dant with fame in reducing the oxi-
dation of  low-density lipoproteins 
to prevent formation of  foam cells 
and thus atherosclerotic plaques. 
Most interest in vitamin E sur-
rounds the cardiovascular issue. 
While the studies are variable most 
point to the fact that vitamin E con-
sumption is associated with some 
degree of  risk reduction in cardio-
vascular disease  with up to 90% of  
Americans not consuming the RDA 
of  15 mg/day. 331-334  Results of  tri-
als of  intervention with vitamin E 
in vascular disease have been totally 
non-definitive. 335-337
In the framework of  diabetes, the 
studies are likewise inconsistent and 
contradictory.338-340 One study does 
however state that oral vitamin E 
treatment appears to be effective in 
normalizing retinal hemodynamic 
abnormalities and improving renal 
function in type 1 diabetic patients 
of  short disease duration without 
inducing a significant change in gly-
cemic control. This suggests that 
vitamin E supplementation may 
provide an additional benefit in 
reducing the risks for developing 
diabetic retinopathy or nephropa-
thy.341
Data from the NHANES 1999-
2000 indicate that mean dietary in-
take of  alpha-tocopherol is 6.3 mg/
day and 7.8 mg/day for women 
and men, respectively.342-342 These 
intakes are well below the current 
intake recommendations of  15 
mg/day.  As previously stated it is 
estimated that more than 90% of  
Americans do not meet daily dietary 
recommendations for vitamin E.344 
Alpha-tocopherol has been shown 
to enhance the immune system. Ad-
ditionally, it works synergistically 
with Omega 3 Fatty Acids to protect 
cells from tumor necrosis factor 
alpha (TNF-a) induced apoptosis. 
Supplementation with Vitamin E 
has also been shown to increase B 
cell activity in the aging patient. 345-346 
Vitamin E also works synergistically 
with Vitamin C to reduce inflamma-
tory prostaglandins and increase T 
cells, IL-2 and tumor necrosis factor 
beta (TNF-B). 
In a prospective observational 
data from a large cohort of  female 
health professionals, higher dietary 
intakes of  lutein/zeaxanthin and 
vitamin E from food and supple-
ments were associated with signifi-
cantly decreased risks of  cataract. 347 
Of  interest, a recent study points to 
the fact that results demonstrated 
that there was no significant differ-
ence between the 600 mg vitamin E 
and placebo groups in the incidence 
of  cataract when vitamin E was 
the only intervention.348 While this 
might surprise some, nutrition and 
health are a combination of  many 
elements. In the realm of  ARMD, 
one study showed evidence that an-
tioxidant (beta-carotene, vitamin C, 
and vitamin E) and zinc supplemen-
tation slowed down the progression 
to advanced AMD and visual acuity 
loss in people with signs of  the dis-
ease, but no evidence that vitamin 
E or beta-carotene prevented AMD. 
349-351 Health is not a single item but 
rather a cornucopia of  actions and 
these two contradictory studies 
point to that.
Upper levels for safety of  con-
sumption of  vitamin E are estab-
lished by the Food and Nutrition 
Board of  the Institute of  Medicine 
to minimize hemorrahage for alpha-
tocopherol supplements are 1,000 
mg/day of  alpha-tocopherol in any 
form (equivalent to 1,500 IU/day 
of  RRR-alpha-tocopherol or 1,100 
IU/day of  all-rac-alpha-tocopher-
ol). One meta-analysis reported that 
to reduce the risk of  any disease 
that 2000 IU/day were necessary 
to reduce the risk by 6%.352 Other 
studies found no evidence of  the 
decrease of  the risk of  death with 
vitamin E supplementation.353-355
Drug interactions must be taken 
into account realizing that hemor-
rhage at excessive dosages is a po-
tential issue. Any pharmaceutical 
agents, foods or supplements such 
as gingko biloba should raise the 
caution of  interaction. 
Scientists at the Linus Pauling 
Institute in Oregon feel there ex-
ists credible evidence that taking a 
supplement of  200 IU (134 mg) of  
natural source d-alpha-tocopherol 
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(RRR-alpha-tocopherol) daily with 
a meal may help protect adults from 
chronic diseases, such as heart dis-
ease, stroke, neurodegenerative 
diseases, and some types of  can-
cer. The amount of  alpha-tocoph-
erol required for such beneficial 
effects appears to be much greater 
than that which could be achieved 
through diet alone. ((lpi.oregonstate.
edu) Controversy reigns with rec-
ommendations on Vitamin E and 
any dosages beyond RDA should 
be carefully considered in view of  
other health and nutritional issues.
Natural sources of  alpha-tocoph-
erol include olive oil, sunflower oil, 
nuts, whole grains , green leafy veg-
etables but usually provide less than 
the RDA of  15 mg/day of  RRR-
alpha-tocopherol.356 Supplements 
made from entirely natural sources 
contain only RRR-alpha-tocopherol 
(also labeled d-alpha-tocopherol). 
RRR-alpha-tocopherol is the isomer 
preferred for use by the body, mak-
ing it the most bioavailable form of  
alpha-tocopherol. Synthetic alpha-
tocopherol is less bioavailable and 
only half  as potent. The formulas 
for conversion to the RRR form are:
n RRR-alpha-tocopherol (natural 
or d-alpha-tocopherol): 
n IU x 0.67 = mg RRR-alpha-
tocopherol
n all-rac-alpha-tocopherol (syn-
thetic or dl-alpha-tocopherol):  
n IU x 0.45 = mg RRR-alpha-
tocopherol.  
Lutein/Zeaxanthin
The yellow color of  the macula 
lutea is due to the presence of  the 
carotenoid pigments lutein and 
zeaxanthin. In contrast to human 
blood and tissues, no other major 
carotenoids including Beta-caro-
tene or lycopene are found in this 
tissue.357 The associations between 
MP density and serum lutein, serum 
zeaxanthin, and adipose lutein con-
centrations are stronger in men than 
in women.358
A number of  studies intended to 
examine trends in a population sug-
gest a link between increased lutein 
and decreased risk of  eye disease:    
In 1994, a National Eye Institute 
(NEI)-supported study indicated 
that consumption of  foods rich in 
carotenoids — particularly green, 
leafy vegetables such as collard 
greens, kale, and spinach — was as-
sociated with a reduced risk of  de-
veloping macular degeneration.359
In 1999, data from the Nurses 
Health Study showed a reduced 
likelihood of  cataract surgery with 
increasing intakes of  lutein and an-
other carotenoid — zeaxanthin. 360
In 1999, the Health Professionals 
Follow-up Study found a trend to-
ward a lower risk of  cataract extrac-
tion with higher intakes of  lutein 
and zeaxanthin. 361
In 1999, a follow-up to an NEI-
supported population-based study — 
called the Beaver Dam Study — con-
cluded that people with diets higher in 
lutein and zeaxanthin had a lower risk 
of  developing cataract. 362
In 2001, data from the Third National 
Health and Nutrition Examination Sur-
vey reported that higher intakes of lu-
tein and zeaxanthin among people ages 
40-59 may be associated with a reduced 
risk of advanced AMD. 363
Conversely, in 1998, the Beaver 
Dam Study found no significant as-
sociation between the risk of  either 
early or advanced AMD in groups 
that had either the highest intakes 
of  lutein and zeaxanthin or the low-
est intakes of  lutein and zeaxanthin. 
The study researchers caution that 
generally, the consumption of  lutein 
and zeaxanthin in this population 
may have been too low to have had 
an impact on the risk of  AMD. 364-365
In the 2004 LAST (Lutein Anti-
oxidant Supplement Trial) study, 90 
AMD patients were supplemented 
daily with an OcuPower supplement 
capsule containing 10 mg of  crystal-
line FloraGLO lutein, 10 mg lutein 
plus a mixed antioxidant formula, 
or placebo for 12 months. The av-
erage American ingests one to two 
mg of  lutein daily. Patients ingesting 
the lutein supplement experienced 
significant improvements in several 
objective measurements of  visual 
function including glare recovery, 
contrast sensitivity, and visual acu-
ity vs. placebo. Patients also expe-
rienced a 50% increase in macular 
pigment density relative to those on 
placebo.366
In the 2007 LAST study it was 
found that individuals with the low-
est Macular Pigment Optical Den-
sity (MPOD) and in greatest need 
of  supplementation, were also likely 
to benefit from lutein or the lutein 
plus antioxidant.367
Another study evaluated a total 
of  1802 women from ages 50 to 
79. These women were described as 
having dietary and serum levels of  
lutein and zeaxanthin either above 
the 78th (high) or below the 28th 
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(low) percentile. The prevalence of  
nuclear cataract was 23% lower in 
the high-diet group compared with 
the low-diet group. Furthermore, 
those in the highest quintile were 
32% less likely to have a nuclear 
cataract compared with the lowest 
quintile. 368
Higher dietary intake of  lutein/
zeaxanthin was independently as-
sociated with decreased likelihood 
of  having neovascular AMD, geo-
graphic atrophy, and large or ex-
tensive intermediate drusen.369-370 In 
non-advanced AMD eyes, a selec-
tive dysfunction in the central reti-
na (0 degrees – 5 degrees ) can be 
improved by the supplementation 
with carotenoids and antioxidants. 
No functional changes are present 
in the more peripheral (5 degrees 
– 20 degrees) retinal areas.371 It has 
been shown that the synergistic ac-
tion of  zeaxanthin and vitamin E or 
C found in one study demonstrates 
the importance of  the antioxidant 
interaction in efficient protection 
of  cell membranes against oxidative 
damage induced by photosensitized 
reactions.372  
One report suggests that lutein 
and zeaxanthin (the only carot-
enoids found in the lens) may retard 
aging of  the lens.373 Another reports 
that observations indicate dietary 
modulation of  diabetic retinopathy 
risk may be possible by increasing 
intakes of  lutein and lycopene-rich 
foods.374 While the studies continue 
to be both prolific and very contro-
versial very interesting conclusions 
have been drawn in juxtaposition. 
On the basis of  one evidence-
based review, the FDA concluded 
that no credible evidence exists for 
a health claim about the intake of  
lutein or zeaxanthin (or both) and 
the risk of  age-related macular de-
generation or cataracts.375 Another 
study states that a higher dietary 
intake of  lutein/zeaxanthin was 
independently associated with de-
creased likelihood of  having neo-
vascular AMD, geographic atrophy, 
and large or extensive intermediate 
drusen.376 A contrary study found 
only alpha-tocopherol and beta-
cryptoxanthin were related to late 
AMD as single antioxidants. On the 
other hand, the carotene and carot-
enoid families as a combination of  
antioxidants were protectively as-
sociated with late AMD. No rela-
tionship was found between serum 
antioxidants and early AMD. Our 
findings support the hypothesis that 
a combination of  serum antioxi-
dants obtained from the traditional 
Japanese diet is protective for late 
AMD, but not for early AMD.377 
Further controversy continues with 
finding stating that persons with in-
termediate age-related macular de-
generation or advanced age-related 
macular degeneration (neovascular 
or central geographic atrophy) in 
one eye should consider taking the 
AREDS-type supplements. Further 
evaluation of  nutritional factors, 
specifically, lutein/zeaxanthin and 
omega-3 fatty acids will be tested in 
a multicenter controlled, random-
ized trial — the Age-Related Eye 
Disease Study 2 (AREDS2).378
No one can even accurately esti-
mate the RDA of  Lutein. One study 
cites the fact that macular con-
centration of  lutein and zeaxantin 
decreases with age, what exacer-
bates harmful effect of  blue light 
on photoreceptors. Lutein and zea-
xantin act as a filter of  the high en-
ergy blue light. Besides, these carot-
enoids are strong antioxidants and 
neutralize light-generated free radi-
cals. Plant foods are the exclusive 
dietary sources of  the carotenoids. 
Their average intake in the Europe-
an countries is several times lower 
than 6 mg daily, which is the esti-
mated recommended intake.379 One 
study is bold enough to say that el-
derly human subjects with and with-
out AMD can safely take supple-
ments of  lutein up to 10 mg/d for 6 
months with no apparent toxicity or 
side effects.380
One study covers the ground pretty 
well stating that observational and 
clinical trials support the safety of  
higher intakes of  the phytochemicals 
lutein and zeaxanthin and their associ-
ation with reducing risks of  cataracts 
in healthy postmenopausal  women 
and improving clinical features of  
AMD in patients. Additional phyto-
chemicals of  emerging interest, like 
green tea catechins, anthocyanins, res-
veratrol, and Ginkgo biloba, shown to 
ameliorate ocular oxidative stress, de-
serve more attention in future clinical 
trials.  Obtuse, yet obtuse.381 Yet an-
other spin, The carotenoid zeaxanthin 
accumulates in the human macula lu-
tea and protects retinal cells from blue 
light damage.
Thus, consumption of  zeaxan-
thin-rich potatoes significantly in-
creases chylomicron zeaxanthin 
concentrations suggesting that po-
tentially such potatoes could be used 
as an important dietary source of  
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zeaxanthin.382 Another study chimes 
in with the assessment that after 
multivariate adjustment for potential 
confounders 1980 energy-adjusted 
intakes of  alpha-carotene, beta-car-
otene, lycopene, total retinol, total 
vitamin A, and total vitamin E were 
significantly inversely related to the 
prevalence of  pigmentary abnor-
malities (PA). Furthermore, increas-
ing frequency of  consuming foods 
high in alpha-or beta-carotene was 
associated with lower odds of  Pig-
mentary Abnormalities.  Alluding to 
the impact of  multiple antioxidants 
on ARMD.383
Another interesting historical 
twist has presented in the nutri-
tional arena as related to lutein. One 
report states that concentrations 
of  serum lutein 26% and zeaxan-
thin 38% increased after 5-wk of  
1 egg/d compared with the phase 
prior to consuming eggs. Serum 
concentrations of  total cholesterol, 
LDL cholesterol, HDL cholesterol, 
and triglycerides were not affect-
ed. These findings indicate that in 
older adults, 5 wk of  consuming 1 
egg/d significantly increases serum 
lutein and zeaxanthin concentra-
tions without elevating serum lipids 
and lipoprotein cholesterol con-
centrations.384 Another report goes 
on to say for these reasons, dietary 
recommendations aimed at restrict-
ing egg consumption should not be 
generalized to include all individuals 
(70% of  the population experiences 
a mild increase or no alterations in 
plasma cholesterol concentrations 
when challenged with high amounts 
of  dietary cholesterol (hypore-
sponders). It appears that diverse 
healthy populations experience no 
risk in developing coronary heart 
disease by increasing their intake 
of  cholesterol but, in contrast, they 
may have multiple beneficial effects 
by the inclusion of  eggs in their 
regular diet.385 In regard to the po-
tential negative cardiovascular risk 
other studies suggest as well a po-
tential contribution of  lutein and 
zeaxanthin to the prevention of  
heart disease and stroke. It is worth 
noting that recommendations to 
consume foods rich in xanthophylls 
are consistent with current dietary 
guidelines. Lutein and zeaxanthin 
are xanthophyll carotenoids found 
particularly in dark-green leafy veg-
etables and in egg yolks. They are 
widely distributed in tissues and are 
the principal carotenoids in most 
tissue throughout the body.386-387 In 
conclusion, the lutein bioavailability 
from egg is higher than that from 
other sources such as lutein, lutein 
ester supplements, and spinach.388
The most provocative informa-
tion to come along in a while is the 
relationship of  Omega 3 fatty acids 
to the entire process of  macular de-
generation, ocular disease and sys-
temic disorders.  While these are not 
covered in detail here, it is impor-
tant to understand the concept of  
inflammation and how it contrib-
utes to ARMD and ocular disorders. 
One study’s objective was to deter-
mine the effects of  lutein (12 mg/d) 
and DHA (800 mg/d) on their se-
rum concentrations and macular 
pigment optical density (MPOD) 
Lutein supplementation increased 
MPOD eccentrically. DHA resulted 
in central increases. These results 
may be due to changes in lipopro-
teins. Lutein and DHA may aid in 
prevention of  age-related macular 
degeneration.389 Another study cor-
roborates the fact that n-3 Fatty 
acids, particularly docosahexaenoic 
acid (DHA), are highly concen-
trated in brain and retinal tissue and 
may prevent or delay the progres-
sion of  dementia and AMD. Low 
dietary intakes and plasma concen-
trations have been reported to be 
associated with dementia, cognitive 
decline, and AMD risk. They go on 
to reports that their own unpub-
lished observations from the Fram-
ingham Heart Study suggest that > 
or =180 mg/d of  dietary DHA (ap-
proximately 2.7 fish servings/wk) 
is associated with an approximately 
50% reduction in dementia risk.  At 
least this amount of  DHA is gen-
erally found in one commercially 
available 1-g fish oil capsule given 
daily.390 Further information regard-
ing inflammation and AMD dem-
onstrated that Linolenic acid was 
positively associated with risk of  
AMD docosahexaenoic acid (DHA) 
had a modest inverse relation with 
AMD and that >4 servings of  fish/
wk was associated with a 35% lower 
risk of  AMD compared with < or = 
3 servings/mo.  Also total fat intake 
was positively associated with risk 
of  AMD. The conclusion was a high 
intake of  fish may reduce the risk of  
AMD.391  Likewise higher levels of  
serum antioxidants vitamin C and 
lutein/zeaxanthin and higher fish 
intake were associated with lower se-
rum C-Reactive Protein (CRP) lev-
els, whereas serum vitamin E, smok-
ing, and increased body mass index 
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were associated with increased CRP. 
Furthermore, serum vitamin E, se-
rum alpha-carotene, and dietary in-
take of  antioxidants and vitamin B6 
were associated with lower levels of  
plasma HCY, whereas hypertension 
was associated with increased HCY. 
C-reactive protein and HCY levels 
are related to traditional dietary and 
behavioral factors associated with 
age-related macular degeneration. 
392 One more study corroborates the 
relationship stating that a higher fre-
quency of  fish consumption was as-
sociated with decreased odds of  late 
ARM.  Subjects with higher energy-
adjusted intakes of  cholesterol were 
significantly more likely to have late 
ARM. The amount and type of  di-
etary fat intake may be associated 
with ARM.393
With review of  the issues of  lu-
tein, ambiguity reigns.  One report 
advocates that vitamins C and E, 
and lutein/zeaxanthin should be 
included in our theoretically ideal 
ocular nutritional supplement.394 
Another understates saying that un-
til scientifically sound knowledge 
is available we recommend for pa-
tients judged to be at risk for AMD 
to: alter their diet to more dark 
green leafy vegetables, wear UV 
protective lenses and a hat when 
outdoors. 395 Lutein and zeaxanthin 
do not exist in a vacuum and the en-
tire issue of  health is multifactorial. 
Diet looms as critically important in 
the genesis of  all disease and AMD 
is not an exception.  An illustration 
of  that is the fact that high con-
sumption of  corn bread indicated 
significant association with central 
vision loss (OR 0.4; 95% CI 0.2, 
0.9)in 168 rural elders.396 This re-
lates to the fact that cross-sectional 
studies indicate that diets that pro-
vide a higher dietary glycemic index 
(dGI) are associated with a greater 
risk of  age-related macular degen-
eration (AMD). Persons at risk of  
AMD progression, especially those 
at high risk of  advanced AMD, may 
benefit from consuming a smaller 
amount of  refined carbohydrates.397 
The association between dietary gly-
cemic index (dGI) and AMD from 
the AREDS cross-sectional analysis 
at baseline suggests that a reduction 
in the dGI, a modifiable risk factor, 
may provide a means of  diminish-
ing the risk of  AMD.398
While Lutein and Zeaxanthin are 
readily available in dark leafy green 
vegetables, patients with concerns 
about blood clotting must avoid 
some of  these because of  the Vita-
min K-clotting factor-in these veg-
etables.  Lutein and Zeaxanthin may 
be supplemented in pill or egg form 
without fear of  interference with 
blood thinners.
Glutathione
Glutathione is the most abundant 
antioxidant in the body, produced in 
the body, found in every cell in the 
body and is the primary free radical 
fighter. It is the regenerator of  im-
mune cells. It is produced in every 
cell with the help of  selenium, mag-
nesium and vitamin C. Glutathione 
production decreases with age.  The 
pathway for collagen remodeling 
and apoptosis induction in glaucoma 
seems to be exogenously influenced 
by water-soluble antioxidants, for 
example, glutathione. The pathway 
for elastin remodelling and apopto-
sis induction seems to be influenced 
by endogenous lipid-soluble anti-
oxidants, for example, vitamin E.399 
Supplementation with glutathione 
is not accomplished well orally and 
the utilization of  supplementation is 
not well documented.  
Magnesium
Magnesium is a mineral and is very 
short acting. The majority of  mag-
nesium is within the skeleton, with 
about 25% in muscle and it is in-
volved in more than 300 essential 
reactions within the body.400 Mag-
nesium is involved in glutathione 
production, cell membrane genesis 
and chromosome activity. As related 
to cellular mechanism magnesium is 
critical in ions transport across cell 
membranes, as evident in the neu-
rodegeneration model. Magnesium 
acts as a smooth muscle relaxant, 
partially inhibits the effect of  en-
dothelin (a vasoconstrictor), and 
is a calcium channel blocker, and 
as such often acts as a vasodilator 
and improves peripheral circula-
tion.401-404 Some studies suggest that 
magnesium plays a role in hyperten-
sion and cardiovascular disease but 
there is no definitive work to under-
score the recommendations for in-
tervention.405-411 Magnesium is very 
involved in the ATP-synthesizing 
protein in mitiochondria and as such 
in the neuroprotection pathway. 412
Magnesium seems to have a benefi-
cial effect on the visual field in glauco-
ma patients with both increased and 
normal IOP — possibly by alleviating 
vasospasm at 300 mg/day.  Magne-
sium also works to activate enzymatic 
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systems.413-414 Magnesium does not 
directly influence immune function 
but rather is critical in 300 enzymatic 
functions in the body. Magnesium 
deficiency causes an increase in pro-
inflammatory cytokines and an excess 
production of  free radicals and as a 
result increases the effects of  the in-
flammatory process.  
Magnesium depletion is com-
monly associated with both insulin 
dependent (IDDM) and non-insu-
lin dependent (NIDDM)diabetes 
mellitus. Between 25% and 38% of  
diabetics have been found to have 
decreased serum levels of  magne-
sium (hypomagnesemia) perhaps 
associated with urinary issues.415 
It is suggested but not proven 
that magnesium supplementation 
may be beneficial in patients with 
diabetes.416-417
From a neurological standpoint, 
persons with recurrent migraines 
have lower magnesium levels.418 
Supplementation to alleviate the 
headaches has produced conflicting 
results and the levels of  supplemen-
tation to achieve modulation of  the 
headaches result in side effects.419-420
Magnesium absorption is impaired 
by a low protein diet, a high fiber 
diet, and excesses in zinc consump-
tion, GI disorders, bariatric surgery 
renal disorders, chronic alcoholism, 
increasing age.421 Magnesium can 
interact with digoxin, anti-malarials, 
some drugs to treat osteoporosis,, 
tranquilizers, oral anticoagulants 
and some antibiotics. In seriously ill 
patients, the primary care physician 
should be consulted.
Consumption of  magnesium in 
the US is considered lower than the 
RDA. Natural sources of  magne-
sium are cereals, brown rice, nuts, 
beans, spinach, chard, okra and 
bananas.  Recommended daily dos-
age is 420 mg/day for men over 30 
and 320 mg/day for women over 
30 years of  age. The recommended 
supplement is 100 mg/day assum-
ing some dietary consumption of  
magnesium. The tolerable upper 
level of  intake (UL), which is 350 
mg/day set by the Food and Nutri-
tion Board.422
Zinc  
Zinc is an essential trace element for 
the proper functioning of  a number 
of  human systems. Zinc is critical 
for 100 different enzymes relevant 
to their catalytic role.423  Zinc is also 
critical in the structure of  proteins 
and cell membranes. Cell mem-
branes are susceptible to oxidative 
damage with loss of  zinc. 424 Zinc 
also has a role in gene expression 
acting in the role of  transcription 
factors as well as having responsi-
bilities in cell signaling. Zinc also 
plays a role in apoptosis.425  
Zinc served the role as the entry 
point for eye care into the realiza-
tion of  the importance of  nutrition 
in ocular health.  Use in the manage-
ment of  macular degeneration has 
resulted in mixed reports. 426-432 The 
element is, however, a part of  the 
AREDS recommendation. When 
speaking about commercially avail-
able vitamin supplements it should 
be noted that zinc at 80 mg/day 
resulted in increase genitourinary 
hospital admissions in the AREDS 
study.433 It has also been found that 
based on the evidence it is suggest 
that zinc plays a role in sub-RPE de-
posit formation in the aging human 
eye and possibly also in the develop-
ment and/or progression of  AMD. 434
Large quantities of  zinc interfere 
with copper bioavailability by induc-
ing intestinal sysnthesis of  metallo-
thionein, which traps copper.435  
This action may then lead to cupric 
anemia.  Zinc consumption must be 
accompanied by copper supplemen-
tation.  Iron supplementation and 
calcium combined with phytic acid 
(limes) may also decrease the avail-
ability of  zinc.436 Zinc is required 
for the enzyme that converts retinol 
(vitamin A) to retinal. Zinc defi-
ciency is associated with decreased 
release of  vitamin A from the liver, 
which may contribute to symptoms 
of  night blindness that are seen 
with zinc deficiency.437 High doses 
of  zinc also impact negatively in the 
absorption of  magnesium.438
Zinc is important in the immune 
system and has gained much press 
in regard to the prevention of  colds 
and respiratory disease and gastro-
intestinal disorders especially as re-
lated to children.439-443 There are also 
implications regarding diarrhea with 
The World Health Organization and 
the United Nations Children’s Fund 
currently recommending zinc supple-
mentation as part of  the treatment for 
diarrheal diseases in young children.444 
A recent meta-analysis of  published 
randomized controlled trials on the 
use of  zinc gluconate lozenges in 
colds found that evidence for their 
effectiveness in reducing the dura-
tion of  common colds was still lack-
ing.445 Use of  intranasal zinc is also of  
questionable value.446-447 with recent 
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removal from the market for loss of  
smell.448 
Zinc picolinate has been pro-
moted as a more absorbable form 
of  zinc, but there are few data to 
support this idea in humans. In or-
der to prevent copper deficiency, 
the U.S. Food and Nutrition Board 
set the tolerable upper level of  
intake (UL) for adults at 40 mg/day, 
including dietary and supplemental 
zinc.449 Most AREDs formulas con-
tain double that recommendation. 
The recommendation for zinc is 
to take a multivitamin supplement 
containing 100% of  the daily values 
(DV) of  most nutrients will gener-
ally provide 15 mg/day of  zinc. Use 
of  zinc may decrease the absorption 
of  tetracyclines and quinolones so 
an interval of  two hours is appro-
priate.450
Natural sources of  zinc include 
crab, oysters, beef, pork, dark meat 
chicken and turkey, yogurt, cheese, 
milk, cashews, almonds, peanuts, 
and beans.  
Zinc is critical in a number of  dif-
ferent interactions in the body but 
in excess there may be danger both 
systemically and in the potentiation 
of  ARMD.
Part 4 of  this series will be a  
continuation of  the discussion of  
the specific supplements and their 
benefits in the management of  dis-
eases and disorders. This will include 
an extensive discussion of  the very 
timely issue of  Omega 3 and Omega 
6 fatty acids. It will be printed in 
Spring, 2010.
Dr. Alexander receives no reimbursement 
from any nutritional supply company. He 
is the Sr. Director of  Clinical Education 
and Professional Relations for Optovue, 
Inc, a digital imaging company, which 
produces the RTVue and has a commit-
ment to the visual well-being of  the world.
References Part 3 CJO
280. Douglas RM, Hemila H, Chalker E, Treacy 
B.  Vitamin C for preventing and treating the 
common cold.  Cochrane Database Syst Rev. 
2007; 18(3):CDOOO980).
281. Stephen R, Utecht T.  Scurvy identified in 
the emergency department: a case report.  J 
Emerg Med 2001;21(3):235-237.
282. Galley HF, Walker BE, Howdle PD, Webster 
NR. Regulation of  nitric oxide synthase 
activity in cultured human endothelial cells: 
effect of  antioxidants. Free Radic Biol Med 
1996;21(1):97-101.
283. Wilson JX.  Antioxidant defense of  the 
brain: a role for astrocytes.  Can J Physiol 
Pharmacol 1997;75(10-11):1149-1164.
284. Taddei S, Virdis A, Ghiadoni L, et al. 
Vitamin C improves endothelium-dependent 
vasodilation by restoring nitric oxide activity 
in essential hypertension.  Circulation 
1998;97(22):2222-2229.
285. Jariyapongskul A, Rungiaroen T, Kasetsuwan 
N, et al. Long-term effects of  oral vitamin 
C supplementation on the endothelial 
dysfunction in the iris microvessels of  
diabetic rats.  Microvasc Res 2007;74(1):32-
38. Epub 2007 Mar 23.
286. Peponis V, Bonovas S, Kapranou A, et al. 
Conjunctival and tear film changes after 
vitamin C and E administration in non-
insulin dependent diabetes mellitus.  Med Sci 
Monit 2004;10(5):CR213-217.
287. Harding AH, Wareham NJ, Bingham SA, et 
al. Plasma vitamin C level, fruit and vegetable 
consumption, and the risk of  new-onset type 
2 diabetes mellitus: the European prospective 
investigation of  cancer—Norfolk prospective 
study.  Arch Intern Med 2008;168(14):1493-
1499.  
288. Zhou JW, Ren GL, Shang XM, et al. Study of  
blue light induced DNA damage of  retinal 
pigment epithelium(RPE) cells and the 
protection of  vitamin C.  Shi Yan Sheng Wu 
Xue Bao 2003;36(5):397-400.
289. Bubowitz A, Assia EI, Rosner M, Topaz 
M. Antioxidant protection against 
corneal damage by free radicals during 
phacoemulsification.  Invest Ophthalmol Vis 
Sci 2003;44(5):1866-1870. 
290. Koliakos GG, Konstas AG, Schlotzer-
Schrehardt U, et al. Ascorbic acid 
concentration is reduced in the aqueous 
humor of  patients with exfoliation syndrome. 
Am J Ophthalmol 2002;134(6):879-883.
291. Mares-Perlman JA, Lyle BJ, Klein R, et 
al. Vitamin supplement use and incident 
cataracts in a population-based study.  Arch 
Ophthalmol 2000;118(11):1556-1563.
292. Taylor A, Jacques PF, Chylack LT Jr, et 
al. Long-term intake of  vitamins and 
carotenoids and odds of  early age-related 
cortical and posterior subcapsular lens 
opacities.  Am J Clin Nutr 2002;75(3):540-
549.
293. No authors listed.  Vitamin C and cataract 
risk in women.  Harv Womens Health Watch 
2002;9(9):1.
294. Food and Nutrition Board, Institute of  
Medicine. Vitamin C. Dietary Reference 
Intakes for Vitamin C, Vitamin E, Selenium, 
and Carotenoids. Washington D.C.: National 
Academy Press; 2000:95-185.
295. Taylor EN, Stampfer MJ, Curhan GC. Dietary 
factors and the risk of  incident kidney stones 
in men: new insights after 14 years of  follow-
up. J Am Soc Nephrol. 2004;15(12):3225-
3232.
296. Holick MF. Vitamin D: importance in the 
prevention of  cancers, type 1 diabetes, heart 
disease, and osteoporosis..  Am J Clin Nutr 
2004;79(3):362-371.
297. Giovannucci E.  Can vitamin D reduce 
total mortality?  Arch Intern Med 
2007;167(16):1709-1710. 
298. Dobnig H, Pilz S, Scharnagl H, et 
al. Independent association of  low 
serum 25-hydroxyvitamin d and 
1,25-dihydroxyvitamin d levels with all-cause 
and cardiovascular mortality.  Arch Intern 
Med 2008;168(12):1340-1349.
299. Martins D, Wolf  M, Pan D, et al. Prevalence 
of  cardiovascular risk factors and the serum 
levels of  25-hydroxyvitamin D in the United 
States: data from the Third National Health 
and Nutrition Examination Survey.  Arch 
Intern Med 2007;167(11):1159-1165.
300. Holick MF.  Vitamin D deficiency.  N Engl J 
Med 2007;357(3):266-281.
301. Wheeler S. American Headache Society 50th 
Annual Scientific Meeting: Abstract S33. 
Presented June 28, 2008.
C a n a d i a n  J o u r n a l  o f  o p t o m e t r y
r e v u e  C a n a d i e n n e  d ’ o p t o m é t r i e
Vol 71  No 5
October / octobre 2009 21
302. Singh H. American Association of  Clinical 
Endocrinologists 17th Annual Meeting and 
Clinical Congress: Abstract 520. Presented 
May 16, 2008. 
303. Griffin MD, Xing N, Kumar R. Vitamin 
D and its analogs as regulators of  immune 
activation and antigen presentation.  Annu 
Rev Nutr 2003;23:117-145.
304. hayes CE, Nashold FE, Spach KM, Pedersen 
LB. The immunological functions of  the 
vitamin D endocrine system..  Cell Mol Biol 
2003;49(2):277-300.  
305. Vieth R, Bischoff-Ferrari H, Boucher BJ, et 
al. The urgent need to recommend an intake 
of  vitamin D that is effective.  Am J Clin 
Nutr 2007;85(3):649-650.
306. Bodnar LM, Simhan HN, Powers RW, et al. 
High prevalence of  vitamin D insufficiency 
in black and white pregnant women residing 
in the northern United States and their 
neonates.  J Nutr 2007;137(2):447-452.
307. Holick MF.  Vitamin D: A millennium 
perspective.  J Cell Biochem 2003;88(2):296-307.  
308. Sutton AL, MacDonald PN. Vitamin D: 
more than a “bone-a-fide” hormone.  Mol 
Endocrinol 2003;17(5):777-791.
309. Guyton KZ, Kensler TW, Posner GH. 
Vitamin D and vitamin D analogs as 
cancer chemopreventive agents. Nutr Rev 
2003;61(7):227-238.
310. McCann JC, Ames BN. Is there convincing 
biological or behavioral evidence linking 
vitamin D deficiency to brain dysfunction?  
FASEB J 2008:22(4):982-1001.
311. Li YC, Kong J, Wei M, et al. 
1,25-Dihydroxyvitamin D(3) is a negative 
endocrine regulator of  the renin-angiotensin 
system.  J Clin Invest 2002;110(2):155-156.
312. Giovannucci E, Liu Y, Hollis BW, Rimm EB. 
25-hydroxyvitamin D and risk of  myocardial 
infarction in men: a prospective study.  Arch 
Intern Med 2008;168(11):1174-1180.
313. Shoben AB, Rudser KD, de Boer IH, et al. 
Association of  oral calcitriol with improved 
survival in nondialyzed CKD.  J Am Soc 
Nephrol 2008;19(8):1613-1619.
314. American Society of  Clinical Oncology 
2008 Annual Meeting: Abstract 511 Preview 
presscast, May 15, 2008.  Appearing in 
Medscape Today May 21, 2008. 
315. Lips P, Hosking D, Lippuner K, et al. 
The prevalence of  vitamin D inadequacy 
amongst women with osteoporosis: an 
international epidemiological investigation.  J 
Intern Med 2006;260(3):245-254.
316. Lips P. Vitamin D deficiency and secondary 
hyperparathyroidism in the elderly: 
consequences for bone loss and fractures 
and therapeutic implications.  Endocr Rev 
2001;22(4):477-501. 
317. Bischoff-Ferrari HA, Willett WC, Wong 
JB, et al. Fracture prevention with vitamin 
D supplementation: a meta-analysis of  
randomized controlled trials.  JAMA 
2005;293(18):2257-2264.
318. Jackson RD, LaCroix AZ, Gass M, et al. 
Calcium plus vitamin D supplementation 
and the risk of  fractures.  N Engl J Med 
2006;354(7):669-683.
319. Armas LA, Hollis BW, Heaney RP. Vitamin 
D2 is much less effective than vitamin 
D3 in humans.  J Clin Endocrinol Metab 
2004;89(11):5387-5391.
320. Houghton LA, Vieth R. The case 
against ergocalciferol (vitamin D2) as 
a vitamin supplement.  Am J Clin Nutr 
2006;84(4):694-697.
321. Food and Nutrition Board, Institute of  
Medicine. Vitamin D. Dietary Reference 
Intakes: Calcium, Phosphorus, Magnesium, 
Vitamin D, and Fluoride. Washington D.C.: 
National Academies Press; 1999:250-287.
322. Vieth R. Vitamin D supplementation, 
25-hydroxyvitamin D concentrations, and 
safety.  Am J Clin Nutr 1999;69(5):842-856.
323. Bischoff-Ferrari HA, Giovannucci E, Willett 
WC, et al. Estimation of  optimal serum 
concentrations of  25-hydroxyvitamin D for 
multiple health outcomes.  Am J Clin Nutr 
2006;84(1):18-28.  
324. Melamed ML, Michos ED, Post W, Astor B. 
25-hydroxyvitamin D levels and the risk of  
mortality in the general population.  Arch 
Intern Med 2008;168(15):1629-1637.  
325. Buhr G, Bales CW. Nutritional 
supplements for older adults: review and 
recommendations-part I.  J Nutr Elder 
2009;28(1):5-29.  
326. Parekh N, Chappell RJ, Millen AE, et al. 
Association between vitamin D and age-
related macular degeneration in the Third 
National Health and Nutrition Examination 
Survey, 1988 through 1994.  Arch 
Ophthalmol 2007;125(5):661-669.
327. Seitzman RL, Mangione CM, Cauley JA, 
et al. Bone mineral density and age-related 
maculopathy in older women.  J Am Geriatr 
Soc 2007;55(5): 740-746.
328. Engin KN.  Alpha-tocopherol: looking 
beyond an antioxidant.  Molecular Vision 
2009;15:855-860.
329. Lee IK, Koya D, Ishi H, et al. d-Alpha-
tocopherol prevents the hyperglycemia 
induced activation of  diacylglycerol (DAG)-
protein kinase C (PKC) pathway in vascular 
smooth muscle cell by an increase of  DAG 
kinase activity.  Diabetes Res Clin Pract 
1999;45(2-3):183-190.
330. Engin KN, Engin G, Kucuksahin H, et al. 
Clinical evaluation of  the neuroprotective 
effect of  alpha-tocopherol against 
glaucomatous damage.  Eur J Ophthalmol 
2007;17(4):528-533.
331. Knekt P, Reunanen A, Jarvinen R, et al. 
Antioxidant vitamin intake and coronary 
mortality in a longitudinal population study.  
Am J Epidemiol 1994:139(12):1180-1189.
332. Cheurbini A, Zuliani G, Costantini F, et al. 
High vitamin E plasma levels and low low-
density lipoprotein oxidation are associated 
with the absence of  atherosclerosis 
in octogenarians.  J Am Geriatr Xoc 
2001;49(5):651-654.
333. Lee IM, Cook NR, Gaziano JM, et al. 
Vitamin E in the primary prevention of  
cardiovascular disease and cancer: the 
Women’s Health Study: a randomized 
controlled trial.  JAMA 2005;294(1):56-65.
334. Traber MG, Frei B, Beckman JS. Vitamin 
E revisited: do new data validate benefits 
for chronic disease prevention?  Curr Opin 
Lipidol 2008;19(1):30-38.
335. Stephens NG, Parsons A, Schofield PM, et 
al. Randomised controlled trial of  vitamin E 
in patients with coronary disease: Cambridge 
Heart Antioxidant Study (CHAOS).  Lancet 
1996;347(9004):781-786. 
336. Boaz M, Smetana S, Weinstein, et al. 
Secondary prevention with antioxidants 
of  cardiovascular disease in endstage 
renal disease (SPACE): randomised 
placebo-controlled trial.  Lancet 
2000;356(9237):1213-1218.
337. Yusuf  S, Dagenais G, Pogue J, et al. Vitamin 
E supplementation and cardiovascular events 
in high-risk patients. The Heart Outcomes 
Prevention Evaluation Study Investigators.  
N Engl J Med 2000;342(3):154-160.
338. Paolisso G, D’Amore A, Giugliano D, et al. 
Pharmacologic doses of  vitamin E improve 
insulin action in healthy subjects and non-
insulin-dependent diabetic patients.  Am J 
Clin Nutr 1993;57(5):650-656.
339. Paolisso G, D’Amore A, Gaizerano D, et 
al. Daily vitamin E supplements improve 
metabolic control but not insulin secretion 
in elderly type II diabetic patients.  Diabetes 
Care 1993;16(11):1433-1437.
C a n a d i a n  J o u r n a l  o f  o p t o m e t r y
r e v u e  C a n a d i e n n e  d ’ o p t o m é t r i e
Vol 71  No 5
October / octobre 200922
340. Jain Sk, McVie R, Jaramillo JJ, et al. Effect of  
modest vitamin E supplementation on blood 
glycated hemoglobin and triglyceride levels 
and red cell indices in type I diabetic patients.  
J Am Coll Nutr 1996;15(5):458-461.
341. Bursell SE, Clermont AC, Aiello LP, et 
al. High-dose vitamin E supplementation 
normalizes retinal blood flow and creatinine 
clearance in patients with type 1 diabetes.  
Dibetes Care 1999;22(8):1245-1251.
342. Ahuja JK, Goldman JD, Moshfegh AJ. 
Current status of  vitamin E nutriture. Ann N 
Y Acad Sci. 2004;1031:387-390.
343. Ford ES, Sowell A. Serum alpha-tocopherol 
status in the United States population: 
findings from the Third National Health 
and Nutrition Examination Survey. Am J 
Epidemiol. 1999;150(3):290-300.
344. Maras JE, Bermudez OI, Qiao N,  et al. 
Intake of  alpha-tocopherol is limited among 
US adults.  J Am Diet Assoc 2004;104(4):567-
575.
345. Meydani SN, Leda LS, Fine BC, et al. Vitamin 
E and respiratory tract infections in elderly 
nursing home residents: a randomized 
controlled trial.  JAMA 2004;292(7):828-836.
346. Han SN, Meydani SN. Vitamin E and 
infectious diseases in the aged.  Proc Nutr 
Soc 1999;58(3):697-705.
347. Christen WG, Liu S, Glynn RJ, et al. Dietary 
carotenoids, vitamins C and E, and risk of  
cataract in women: a prospective study.  Arch 
Ophthalmol 2008;126(1):102-109.
348. Christen WG, Glynn RJ, Chew EY, Buring 
JE. Vitamin E and age-related cataract in a 
randomized trial of  women.  Ophthalmology 
2008;115(5):822-829.
349. Evans J. Antioxidant supplements to prevent 
or slow down the progression of  AMD: a 
systematic review and meta-analysis.  Eye 
2008;22(6):751-760.
350. Evans JR, Henshaw K. Antioxidant vitamin 
and mineral supplements for preventing 
age-related macular degeneration.  Cochrane 
Database Syst Rev 2008;(1):CD000253.
351. Chong EW, Wong TY, Kreis AJ, et al. 
Dietary antioxidants and primary prevention 
of  age related macular degeneration: 
systematic review and meta-analysis.  BMJ 
2007;335(7623):755.
352. Miller ER 3rd, Pasotr-Barriuso R, Dalal, 
et al. Meta-analysis: high-dosage vitamin 
E supplementation may increase all-cause 
mortality.  Ann Intern Med 2005;142(1):37-
46.
353. Shekelle PG, Morton SC, Jungvig LK, et al. 
Effect of  supplemental vitamin E for the 
prevention and treatment of  cardiovascular 
disease.  J Gen Intern Med 2004;19(4):380-
389.
354. Eidelman RS, Hollar D, Hebert PR. 
Randomized trials of  vitamin E in the 
treatment and prevention of  cardiovascular 
disease.  Arch Intern Med 2004;164(14):1552-
1556.
355. Bjelakovic G, Nikolova D, Gluud LL, et al. 
Mortality in randomized trials of  antioxidant 
supplements for primary and secondary 
prevention: systematic review and meta-
analysis.  JAMA 2007;297(8):842-857. 
356. Food and Nutrition Board, Institute of  
Medicine. Vitamin E. Dietary reference 
intakes for vitamin C, vitamin E, selenium, 
and carotenoids. Washington D.C.: National 
Academy Press; 2000:186-283.
357. Stahl W. Macular carotenoids: lutein and 
zeaxanthin.  Dev Ophthalmol 2005;38:70-88.
358. Broekmans WM, Berendschot TT, Klopping-
Ketelaars IA, et al. Macular pigment 
density in relation to serum and adipose 
tissue concentrations of  lutein and serum 
concentrations of  zeaxanthin.  Am J Clin 
Nutr 2002;76(3):595-603.
359. Seddon JM, Ajani UA, Sperduto RD, et 
al. Dietary carotenoids, vitamins A, C, 
and E, and advanced age-related macular 
degeneration. Eye Disease Case-Control 
Study Group.  JAMA 1994;272(18):1413-
1420.
360. Chasan-Taber L, Willett WC, Seddon JM, 
et al. A prospective study of  carotenoid 
and vitamin A intakes and risk of  cataract 
extraction in US women.  Am J Clin Nutr 
1999;70(4):431-432.
361. Brown L, Rimm EB, Seddon JM, et al. A 
prospective study of  carotenoid intake and 
risk of  cataract extraction in US men.  Am J 
Clin Nutr 1999;70(4):517-524.
362. Lyle BJ, Mares-Perlman JA, Klein R, et al. 
Serum carotenoids and tocopherols and 
incidence of  age-related nuclear cataract.  Am 
J Clin Nutr 1999;69(2):272-277.
363. Mares-Perlman JA, Fisher AI, Klein R, et al. 
Lutein and zeaxanthin in the diet and serum 
and their relation to age-related maculopathy 
in the third national health and nutrition 
examination survey.  Am J Epidemiol 
2001;153(5):424-432.
364. Mares-Perlman JA, Klein R, Klein BE, 
et al. Association of  zinc and antioxidant 
nutrients with age-related maculopathy.  Arch 
Ophthalmol 1996;114(8):991-997.
365. VandenLangenberg GM, Mares-Perlman 
JA, Klein R, et al. Associations between 
antioxidant and zinc intake and the 5-year 
incidence of  early age-related maculopathy in 
the Beaver Dam Eye Study.  Am J Epidemiol 
1998;148(2):204-214.
366. Richer S, Stiles W, Statkute L, et al. Double-
masked, placebo-controlled, randomized trial 
of  lutein and antioxidant supplementation 
in the intervention of  atrophic age-related 
macular degeneration: the Veterans LAST 
study (Lutein Antioxidant Supplementation 
Trial).  Optometry 2004;75(4):216-230
367. Richer S, Devenport J, Lang JC. LAST II: 
Differential temporal responses of  macular 
pigment optical density in patients with 
atrophic age-related macular degeneration to 
dietary supplementation with xanthophylls.  
Optometry 2007;78(5):213-219.
368. Moeller SM, Voland R, Tinker, et al. 
Associations between age-related nuclear 
cataract and lutein and zeaxanthin in the 
diet and serum in the Carotenoids in the 
Age-Related Eye Disease Study, an Ancillary 
Study of  the Women’s Health Initiative.  Arch 
Ophthalmol 2008;126(3);354-364.
369. Age-Related Eye Disease Study Research 
Group, SanGiovanni JP, Chew EY, Clemons 
TE, et al. The relationship of  dietary 
carotenoid and vitamin A, E, and C intake 
with age-related macular degeneration in a 
case-control study: AREDS Report No. 22.  
Arch Ophthalmol 2007;125(9):1225-1232.
370. Tan JS, Wang JJ, Flood V, et al. Dietary 
antioxidants and the long-term incidence 
of  age-related macular degeneration: the 
Blue Mountains Eye Study.  Ophthalmology 
2008;115(2):334-341.
371. Parisi V, Tedeschi M, Gallinaro G, et al.  
CARMIS Study Group. Carotenoids and 
antioxidants in age-related maculopathy 
Italian study: multifocal electroretinogram 
modifications after 1 year.  Ophthalmology 
2008;115(2):324-333.
372. Wrona M, Rozanowska M, Sarna T. 
Zeaxanthin in combination with ascorbic acid 
or alpha-tocopherol protects ARPE-19 cells 
against photosensitized peroxidation of  lipids. 
Free Radic Biol Med 2004;36(9):1094-1101. 
373. Berendschot TT, Broekmans WM, Klöpping-
Ketelaars IA, et al. Lens aging in relation 
to nutritional determinants and possible 
risk factors for age-related cataract.  Arch 
Ophthalmol 2002;120(12):1732-1737.
374. Brazionis L, Rowley K, Itsiopoulos C, 
O’Dea K. Plasma carotenoids and diabetic 
retinopathy.  Br J Nutr 2009;101(2):270-277.
375. Trumbo PR, Ellwood KC. Lutein and 
zeaxanthin intakes and risk of  age-related 
macular degeneration and cataracts: an 
evaluation using the Food and Drug 
C a n a d i a n  J o u r n a l  o f  o p t o m e t r y
r e v u e  C a n a d i e n n e  d ’ o p t o m é t r i e
Vol 71  No 5
October / octobre 2009 23
Administration’s evidence-based review 
system for health claims.  Am J Clin Nutr 
2006;84(5):971-974.  
376. Age-Related Eye Disease Study Research 
Group, SanGiovanni JP, Chew EY, Clemons 
TE, et al. The relationship of  dietary 
carotenoid and vitamin A, E, and C intake 
with age-related macular degeneration in a 
case-control study: AREDS Report No. 22.  
Arch Ophthalmol 2007;125(9):1225-1232.
377. Michikawa T, Ishida S, Nishiwaki Y, et al. 
Serum antioxidants and age-related macular 
degeneration among older Japanese.  Asia Pac 
J Clin Nutr 2009;18(1):1-7.
378. Coleman H, Chew E. Nutritional 
supplementation in age-related macular 
degeneration.  Curr Opin Ophthalmol 
2007;18(3):220-223.
379. Carpentier S, Knaus M, Suh M. Associations 
between lutein, zeaxanthin, and age-related 
macular degeneration: an overview.  Crit Rev 
Food Sci Nutr 2009;49(4):313-326.
380. Khachik F, de Moura FF, Chew EY, et 
al. The effect of  lutein and zeaxanthin 
supplementation on metabolites of  these 
carotenoids in the serum of  persons aged 
60 or older.  Invest Ophthalmol Vis Sci 
2006;47(12):5234-5242. 
381. Rhone M, Basu A. Phytochemicals 
and age-related eye diseases.  Nutr Rev 
2008;66(8):465-472.  
382. Bub A, Moseneder J, Wenzel G, Rechkemmer 
G, Briviba K. Zeaxanthin is bioavailable from 
genetically modified zeaxanthin-rich potatoes. 
Eur J Nutr 2008;47(2):99-103.
383. Morris MS, Jacques PF, Chylack LT, et al. 
Intake of  zinc and antioxidant micronutrients 
and early age-related maculopathy lesions.  
Ophthalmic Epidemiol 2007;14(5):288-298.   
384. Goodrow EF, Wilson TA, Houde SC, et al. 
Consumption of  one egg per day increases 
serum lutein and zeaxanthin concentrations 
in older adults without altering serum lipid 
and lipoprotein cholesterol concentrations.  J 
Nutr 2006;136(10):2519-2524.
385. Fernandez ML. Dietary cholesterol provided 
by eggs and plasma lipoproteins in healthy 
populations.  Curr Opin Clin Nutr Metab 
Care 2006;9(1):8-12.
386. Kritchevsky SB. A review of  scientific 
research and recommendations regarding 
eggs.  J Am Coll Nutr 2004;23(6 Suppl):596S-
600S.
387. Ribaya-Mercado JD, Blumberg JB. Lutein 
and zeaxanthin and their potential roles in 
disease prevention. J Am Coll Nutr 2004;23(6 
Suppl):567S-587S.
388. Chung HY, Rasmussen HM, Johnson EJ. 
Lutein bioavailability is higher from lutein-
enriched eggs than from supplements and 
spinach in men.  J Nutr 2004;134(8):1887-
1893.
389. Johnson EJ, Chung HY, Caldarella 
SM, Snodderly DM. The influence of  
supplemental lutein and docosahexaenoic 
acid on serum, lipoproteins, and 
macular pigmentation.  Am J Clin Nutr 
2008;87(5):1521-1529.  
390. Johnson EJ, Schaefer EF. Potential role of  
dietary n-3 fatty acids in the prevention of  
dementia and macular degeneration.
391. Am J Clin Nutr 2006;83(6Suppl):1494S-
1498S).  
392. Cho E, Hung S, Willett WC, et al. Prospective 
study of  dietary fat and the risk of  age-
related macular degeneration.  Am J Clin 
Nutr 2001;73(2):209-218.
393. Seddon JM, Gensler G, Klein ML, Milton 
RC. C-reactive protein and homocysteine are 
associated with dietary and behavioral risk 
factors for age-related macular degeneration.  
Nutrition 2006;22(4):441-443.
394. Smith W, Mitchell P, Leeder SR. Dietary fat 
and fish intake and age-related maculopathy.  
Arch Ophthalmol 2000;118(3):401-404.
395. Bartlett H, Eperjesi F.  An Ideal ocular 
nutritional supplement?
396. Ophthalmic Physiol Opt 2004;24(4):339-349.
397. Mozaffarieh M, Sacu S, Wedrich A. The role 
of  the carotenoids, lutein and zeaxanthin, 
in protecting against age-related macular 
degeneration: a review based on controversial 
evidence.  Nutr J 2003;2:20.
398. Holcomb CA, Consumption of  caroltenoid-
rich foods and central vision loss:a matched 
case-controlled study in Kansas.  J Nutr Elder 
2004;24(1):1-18.  
399. Chiu CJ, Milton RC, Klein R, et al. Dietary 
carbohydrate and the progression of  age-
related macular degeneration: a prospective 
study from the Age-Related Eye Disease 
Study.  Am J Clin Nutr 2007;86(4):1210-1218.
400. Chiu CJ, Milton RC, Gensler G, Taylor 
A. Association between dietary glycemic 
index and age-related macular degeneration 
in nondiabetic participants in the Age-
Related Eye Disease Study.  Am J Clin Nutr 
2007;86(1):180-188. 
401. Veach J. Functional dichotomy: glutathione 
and vitamin E in homeostasis relevant to 
primary open-angle glaucoma.  Br J Nutr 
2004;91(6):809-829.  
402. Spencer H, Norris C, Williams D. Inhibitory 
effects of  zinc on magnesium balance and 
magnesium absorption in man.  J Am Coll 
Nutr 1994;13(5):479-484.
403. Shechter M, Sharir M, Labrador MJ, et 
al. Oral magnesium therapy improves 
endothelial function in patients with 
coronary artery disease.  Circulation 
2000;102(19):2352-2358.
404. Dettmann ES, Luscher TF, Flammer J, 
Haefliger IO. Modulation of  endothelin-1-
induced contractions by magnesium/calcium 
in porcine ciliary arteries. Graefes Arch Clin 
Exp Ophthalmol 1998;236(1):47-51.
405. Shechter M, Merz CN, Paul-Labrador M, et 
al. Oral magnesium supplementation inhibits 
platelet-dependent thrombosis in patients 
with coronary artery disease.  Am J Cardiol. 
1999;84(2):152-156.
406. Gaspar AZ, Gasser P, Flammer J. The 
influence of  magnesium on visual field 
and peripheral vasospasm in glaucoma.  
Ophthalmologica 1995;209(1):11-13.
407. Song Y, Manson JE, Cook NR, et al. Dietary 
magnesium intake and risk of  cardiovascular 
disease among women.  Am J Cardiol. 
2005;96(8):1135-1141.
408. Ascherio A, Rimm EB, Giovannucci EL, 
et al. A prospective study of  nutritional 
factors and hypertension among US men.  
Circulation. 1992;86(5):1475-1484.
409. Liao F, Folsom AR, Brancati FL. Is low 
magnesium concentration a risk factor for 
coronary heart disease? The Atherosclerosis 
Risk in Communities (ARIC) Study.  Am 
Heart J. 1998;136(3):480-490.
410. Ascherio A, Hennekens C, Willett WC, et 
al. Prospective study of  nutritional factors, 
blood pressure, and hypertension among US 
women.Hypertension. 1996;27(5):1065-1072.
411. Peacock JM, Folsom AR, Arnett DK, 
et al. Relationship of  serum and dietary 
magnesium to incident hypertension: the 
Atherosclerosis Risk in Communities (ARIC) 
Study.  Ann Epidemiol. 1999;9(3):159-165.
412. Sontia B, Touyz RM. Role of  magnesium 
in hypertension.  Arch Biochem Biophys. 
2007;458(1):33-39.
413. Dickinson HO, Mason JM, Nicolosn DF, et 
al. Lifestyle interventions to reduce raised 
blood pressure: a systematic review of  
randomized controlled trials.  J Hypertens. 
2006;24(2):215-233.
414. Rude RK, Shils ME. Magnesium. In: Shils 
ME, Shike M, Ross AC, Caballero B, Cousins 
RJ, eds. Modern Nutrition in Health and 
Disease. 10th ed. Baltimore: Lippincott 
Williams & Wilkins; 2006:223-247.
C a n a d i a n  J o u r n a l  o f  o p t o m e t r y
r e v u e  C a n a d i e n n e  d ’ o p t o m é t r i e
Vol 71  No 5
October / octobre 200924
415. Gaspar AZ, Gasser P, Flammer J. The 
influence of  magnesium on visual field 
and peripheral vasospasm in glaucoma.  
Ophthalmologica 1995;209(1):11-13.
416. Winterkorn JM. The influence of  magnesium 
on visual field and peripheral vasospasm in 
glaucoma.  Surv Ophthalmol 1995;209(1):83-4.
417. Tosiello L. Hypomagnesemia and diabetes 
mellitus. A review of  clinical implications.  
Arch Intern Med. 1996;156(11):1143-1148.
418. Rodriguez-Moran M, Guerrero-Romero F. 
Oral magnesium supplementation improves 
insulin sensitivity and metabolic control 
in type 2 diabetic subjects: a randomized 
double-blind controlled trial. Diabetes Care. 
2003;26(4):1147-1152.
419. Song Y, He K, Levitan EB, et al. Effects 
of  oral magnesium supplementation on 
glycaemic control in Type 2 diabetes: a 
meta-analysis of  randomized double-
blind controlled trials.  Diabet Med. 
2006;23(10):1050-1056.
420. Mauskop A, Altura BM. Role of  magnesium 
in the pathogenesis and treatment of  
migraines.  Clin Neurosci. 1998;5(1):24-27.
421. Wang, F, Van Den Eeden SK, Ackerson LM, 
et al. Oral magnesium oxide prophylaxis of  
frequent migrainous headache in children: a 
randomized, double-blind, placebo-controlled 
trial.  Headache. 2003;43(6):601-610. 
422. Pfaffenrath V, Wessely P, Meyer C, et al. 
Magnesium in the prophylaxis of  migraine-
-a double-blind placebo-controlled study.  
Cephalalgia. 1996;16:436-440.
423. Schwartz R, Walker G, Linz MD, MacKellar 
I. Metabolic responses of  adolescent boys to 
two levels of  dietary magnesium and protein. 
I. Magnesium and nitrogen retention.  Am J 
Clin Nutr. 1973;26:510-518.
424. Food and Nutrition Board, Institute of  
Medicine. Magnesium. Dietary Reference 
Intakes: Calcium, Phosphorus, Magnesium, 
Vitamin D, and Fluoride. Washington D.C.: 
National Academy Press; 1997:190-249.
425. Food and Nutrition Board, Institute 
of  Medicine. Zinc. Dietary reference 
intakes for vitamin A, vitamin K, boron, 
chromium, copper, iodine, iron, manganese, 
molybdenum, nickel, silicon, vanadium, and 
zinc. Washington, D.C.: National Academy 
Press; 2001:442-501.
426. O’Dell BL. Role of  zinc in plasma membrane 
function. J Nutr. 2000;130(5S Suppl):1432S-
1436S.
427. Truong-Tran AQ, Ho LH, Chai F, Zalewski 
PD. Cellular zinc fluxes and the regulation of  
apoptosis/gene-directed cell death. J Nutr. 
2000;130(5S Suppl):1459S-1466S. 
428. Newsome DA, Swartz M, Leone NC, 
Elston RC, Miller E. Oral zinc in 
macular degeneration. Arch Ophthalmol. 
1988;106(2):192-198.  
429. Evans JR. Antioxidant vitamin and mineral 
supplements for slowing the progression of  
age-related macular degeneration. Cochrane 
Database Syst Rev. 2006;(2):CD000254.
430. VandenLangenberg GM, Mares-Perlman 
JA, Klein R, Klein BE, Brady WE, Palta M. 
Associations between antioxidant and zinc 
intake and the 5-year incidence of  early age-
related maculopathy in the Beaver Dam Eye 
Study. Am J Epidemiol. 1998;148(2):204-214. 
431. Smith W, Mitchell P, Webb K, Leeder 
SR. Dietary antioxidants and age-related 
maculopathy: the Blue Mountains Eye Study. 
Ophthalmology. 1999;106(4):761-767.
432. Cho E, Stampfer MJ, Seddon JM, et al. 
Prospective study of  zinc intake and the risk 
of  age-related macular degeneration. Ann 
Epidemiol. 2001;11(5):328-336.
433. Stur M, Tittl M, Reitner A, Meisinger V. 
Oral zinc and the second eye in age-related 
macular degeneration. Invest Ophthalmol 
Vis Sci. 1996;37(7):1225-1235.  
434. A randomized, placebo-controlled, clinical 
trial of  high-dose supplementation with 
vitamins C and E, beta carotene, and zinc 
for age-related macular degeneration and 
vision loss: AREDS report no. 8. Arch 
Ophthalmol. 2001;119(10):1417-1436. 
435. Johnson AR, Munoz A, Gottlieb JL, 
Jarrard DF. High dose zinc increases 
hospital admissions due to genitourinary 
complications.  J Urol 2007;177(2):639-643.
436. Lengyel I, Flinn JM, Peto T, et al. High 
concentration of  zinc in sub-retinal 
pigment epithelial deposits.  Exp Eye Res 
2007;84(4):772-780.
437. King JC, Cousins RJ. Zinc. In: Shils ME, 
Shike M, Ross AC, Caballero B, Cousins 
RJ, eds. Modern Nutrition in Health and 
Disease. 10th ed. Baltimore: Lippincott 
Williams & Wilkins; 2006:271-285.
438. Sandstrom B. Micronutrient interactions: 
effects on absorption and bioavailability.  Br 
J Nutr. 2001;85 Suppl 2:S181-S185.  
439. Hambidge M.  Human zinc deficiency.  J 
Nutr. 2000;130(5S Suppl):1344S-S1349S.
440. Spencer H, Norris C, Williams D. Inhibitory 
effects of  zinc on magnesium balance and 
magnesium absorption in man.  J Am Coll 
Nutr. 1994;13(5):479-484.
441. Bhutta ZA, Black RE, Brown KH, et al. 
Prevention of  diarrhea and pneumonia 
by zinc supplementation in children in 
developing countries: pooled analysis 
of  randomized controlled trials. Zinc 
Investigators’ Collaborative Group. J Pediatr. 
1999;135(6):689-697.
442. Sazawal S, Black RE, Ramsan M, et al. Effect 
of  zinc supplementation on mortality in 
children aged 1-48 months: a community-
based randomised placebo-controlled trial. 
Lancet. 2007;369(9565):927-934.
443. Fortes C, Forastiere F, Agabiti N, et 
al. The effect of  zinc and vitamin A 
supplementation on immune response in 
an older population. J Am Geriatr Soc. 
1998;46(1):19-26.
444. Fischer Walker CL, Black RE. Micronutrients 
and diarrheal disease. Clin Infect Dis. 
2007;45 Suppl 1:S73-77.
445. Aggarwal R, Sentz J, Miller MA. Role of  zinc 
administration in prevention of  childhood 
diarrhea and respiratory illnesses: a meta-
analysis. Pediatrics. 2007;119(6):1120-1130.
446. The United Nations Children’s Fund/World 
Health Organization. WHO/UNICEF Joint 
Statement: Clinical Management of  Acute 
Diarrhoea. Geneva; New York; 2004:1-
8.  Available at: http://www.unicef.org/
publications/index_21433.html
447. Jackson JL, Lesho E, Peterson C. Zinc and 
the common cold: a meta-analysis revisited. J 
Nutr. 2000;130(5S Suppl):1512S-1515S.  
448. Belongia EA, Berg R, Liu K. A randomized 
trial of  zinc nasal spray for the treatment of  
upper respiratory illness in adults. Am J Med. 
2001;111(2):103-108.
449. Eby GA, Halcomb WW. Ineffectiveness of  
zinc gluconate nasal spray and zinc orotate 
lozenges in common-cold treatment: a 
double-blind, placebo-controlled clinical trial. 
Altern Ther Health Med. 2006;12(1):34-38. 
450. DeCook CA, Hirsch AR. Anosmia due to 
inhalational zinc: a case report. Chem Senses. 
2000;25(5):659. 
451. Food and Nutrition Board, Institute 
of  Medicine. Zinc. Dietary reference 
intakes for vitamin A, vitamin K, boron, 
chromium, copper, iodine, iron, manganese, 
molybdenum, nickel, silicon, vanadium, and 
zinc. Washington, D.C.: National Academy 
Press; 2001:442-501.
452. Minerals. In Drug Facts and Comparisons. 
St. Louis, MO: Facts and Comparisons, 
2000:27-51.
